Is the nuclear medicine community too self-critical?

1994 ◽  
Vol 21 (7) ◽  
pp. 698-698
Author(s):  
A. Bossuyt
Keyword(s):  
Nuclear Medicine ◽  
Medicine Community ◽  
Nuclear Medicine Community

scholarly journals Time for radiobiology in the nuclear medicine community

2011 ◽  
Vol 38 (7) ◽  
pp. 1267-1269 ◽  
Author(s):  
Marco Chianelli ◽  
Alberto Signore ◽  
Luigi Mansi ◽  
Massimo Salvatori
Keyword(s):  
Nuclear Medicine ◽  
Medicine Community ◽  
Nuclear Medicine Community

scholarly journals Radioligands Targeting Fibroblast Activation Protein (FAP)

Cancers ◽  
2021 ◽  
Vol 13 (22) ◽  
pp. 5744
Author(s):  
Thomas Lindner ◽  
Frederik L. Giesel ◽  
Clemens Kratochwil ◽  
Sebastian E. Serfling
Keyword(s):  
Nuclear Medicine ◽  
Fibroblast Activation Protein ◽  
Pharmaceutical Companies ◽  
Radioligand Therapy ◽  
Comprehensive Overview ◽  
Fibroblast Activation ◽  
Dietary Restrictions ◽  
18F Fdg ◽  
Medicine Community ◽  
Significant Attention

Targeting fibroblast activation protein (FAP) in cancer-associated fibroblasts (CAFs) has attracted significant attention in nuclear medicine. Since these cells are present in most cancerous tissues and FAP is rarely expressed in healthy tissues, anti-FAP tracers have a potential as pan-tumor agents. Compared to the standard tumor tracer [18F]FDG, these tracers show better tumor-to-background ratios (TBR) in many indications. Unlike [18F]FDG, FAP-targeted tracers do not require exhausting preparations, such as dietary restrictions on the part of the patient, and offer the possibility of radioligand therapy (RLT) in a theragnostic approach. Although a radiolabeled antibody was clinically investigated as early as the 1990s, the breakthrough event for FAP-targeting in nuclear medicine was the introduction and clinical application of the so-called FAPI-tracers in 2018. From then, the development and application of FAP-targeted tracers became hot topics for the radiopharmaceutical and nuclear medicine community, and attracted the interest of pharmaceutical companies. The aim of this review is to provide a comprehensive overview of the development of FAP-targeted radiopharmaceuticals and their application in nuclear medicine.

Maximum image restoration in nuclear medicine

1990 ◽  
Vol 137 (3) ◽  
pp. 163 ◽  
Author(s):  
V.A. Oliveira ◽  
J.M. Nightingale
Keyword(s):  
Nuclear Medicine ◽  
Image Restoration
Sign in / Sign up

Export Citation Format

Share Document